What is DMAA?
DMAA is 1,3-dimethylamylamine, a stimulant compound investigated in small human physiological studies. Its presence in a research catalog does not establish a beneficial performance effect.
Mechanism & research focus
Stimulant and pressor effects are the principal research context. In one acute study, increased blood pressure was not explained by measured circulating norepinephrine or epinephrine, so a simple catecholamine-release explanation is insufficient.
What the research covers
A randomized crossover study in ten healthy adults found increased blood pressure and rate-pressure product with DMAA, including conditions combined with caffeine. A separate small study characterized its pharmacokinetics and found different acute physiological responses under its specific conditions.
What remains uncertain
Small, brief studies cannot establish long-term cardiovascular safety, rare-event risk or performance benefit. Findings vary with exposure and study conditions. The absence of a marked effect in one experiment should not override the pressor signal in another.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
DMAA and caffeine effects on heart rate and blood pressure ↗
Acute blood-pressure and cardiac-workload increases in a small study.
Physiological and pharmacokinetic effects of DMAA in men ↗
Short-term exposure characterization; insufficient for broad safety conclusions.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: DMAA research guide ↗